Altamira Therapeutics Ltd. CYTOF
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | 41.84% | 400.10% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 8.53% | -112.69% | -- |
| Total Operating Expenses | -- | -- | 87.40% | 347.73% | -- |
| Operating Income | -- | -- | -87.40% | -329.39% | -- |
| Income Before Tax | -- | -- | -86.96% | -15.10% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -86.96% | -14.67% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -42.27% | 58.04% | -- |
| EBIT | -- | -- | -87.40% | -329.39% | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -- | -- | 94.26% | 92.54% | -- |
| Normalized Basic EPS | -- | -- | 85.03% | -102.38% | -- |
| EPS Diluted | -- | -- | 94.26% | 92.54% | -- |
| Normalized Diluted EPS | -- | -- | 85.03% | -102.38% | -- |
| Average Basic Shares Outstanding | -- | -- | 1,143.19% | 1,665.11% | -- |
| Average Diluted Shares Outstanding | -- | -- | 910.36% | 1,116.37% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |